FCSC / Fibrocell Science Inc. - Документы SEC, Годовой отчет, Доверенное заявление

FCSC / Fibrocell Science Inc. 15-12B - - 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-31564 FIBROCELL SCIENCE, INC. (Exact name of registrant as specified in

FCSC / Fibrocell Science Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on December 13, 2019 Registration Statement No.

FCSC / Fibrocell Science Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on December 13, 2019 Registration Statement No.

FCSC / Fibrocell Science Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on July 27, 2018 Registration Statement No.

FCSC / Fibrocell Science Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2019 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Amended and Restated Certificate of Incorporation of the Company.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Fibrocell Science, Inc. (a Delaware corporation) December 13, 2019 ARTICLE I. The name of the Corporation is Fibrocell Science, Inc. (the “Corporation”). ARTICLE II. The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of it

FCSC / Fibrocell Science Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2019 Registration No.

FCSC / Fibrocell Science Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2019 Registration No.

FCSC / Fibrocell Science Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2019 Registration No.

Amended and Restated Bylaws of the Company.

Exhibit 3.2 amended and restateD Bylaws of fibrocell science, inc. (a Delaware corporation) Adopted as of December 13, 2019 PREAMBLE These Bylaws are subject to, and governed by, the General Corporation Law of the State of Delaware (as amended, the “DGCL”) and the certificate of incorporation of Fibrocell Science, Inc., a Delaware corporation (the “Corporation”) then in effect (the “Certificate of

FCSC / Fibrocell Science Inc. POS AM - - POS AM

POS AM 1 a19-249773posam.htm POS AM As filed with the Securities and Exchange Commission on December 13, 2019 Registration Statement No. 333-229307 Registration Statement No. 333-209077 Registration Statement No. 333-185466 Registration Statement No. 333-185463 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT

FCSC / Fibrocell Science Inc. POS AM - - POS AM

POS AM 1 a19-249792posam.htm POS AM As filed with the Securities and Exchange Commission on July 27, 2018 Registration Statement No. 333-226397 Registration Statement No. 333-221375 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT NO. 333-226397 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT

FCSC / Fibrocell Science Inc. POS AM - - POS AM

As filed with the Securities and Exchange Commission on December 13, 2019 Registration Statement No.

FCSC / Fibrocell Science Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on December 13, 2019 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

FCSC / Fibrocell Science Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant a

Side Letter Agreement, dated September 12, 2019 by and between Castle Creek Pharmaceutical Holdings, Inc., Castle Creek Pharmaceuticals, LLC and Fibrocell Science, Inc.

Exhibit 10.5 FIBROCELL SCIENCE, INC. 405 Eagleview Boulevard Exton, Pennsylvania 19341 September 12, 2019 CASTLE CREEK PHARMACEUTICAL HOLDINGS, INC. CASTLE CREEK PHARMACEUTICALS, LLC Re: Agreement and Plan of Merger Ladies and Gentlemen: Reference is hereby made to the Agreement and Plan of Merger, executed contemporaneously herewith (the “Merger Agreement”), by and among Fibrocell Science, Inc.,

FCSC / Fibrocell Science Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6

FCSC / Fibrocell Science Inc. DEFM14A - - DEFM14A

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

FCSC / Fibrocell Science Inc. PREM14A - - PREM14A

PREM14A 1 a2239857zprem14a.htm PREM14A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorpor

FCSC / Fibrocell Science Inc. / Klein Roger M. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fibrocell Science, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 315721407 (CUSIP Number) 9/20/2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur

FCSC / Fibrocell Science Inc. / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Exhibit 3

EX-3 2 ex3.htm EXHIBIT 3 Exhibit 3 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Fibrocell Science, Inc., and further agree that this Joint Filing Agreem

Consent and Termination Agreement, dated as of September 12, 2019 among Fibrocell Science, Inc. Castle Creek Pharmaceutical Holdings, Inc. and MSD Credit Opportunity Master Fund, L.P. (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed on September 13, 2019).

Exhibit 10.2 CONSENT AND TERMINATION AGREEMENT THIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), MSD Credit Opportunity Master Fund, L.P., a Cayman exempt lim

Agreement and Plan of Merger, dated as of September 12, 2019, among Fibrocell Science, Inc., Castle Creek Pharmaceutical Holdings, Inc., and Castle Creek Merger Corp.

QuickLinks - Click here to rapidly navigate through this document Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CASTLE CREEK PHARMACEUTICAL HOLDINGS, INC., CASTLE CREEK MERGER CORP. and FIBROCELL SCIENCE, INC. Dated as of September 12, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1. The Merger 2 1.2. Closing and Effective Time of the Merger 3 ARTICLE II CONVERSION OF SECURITIES IN

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Consent and Termination Agreement, dated as of September 12, 2019, among Fibrocell Science, Inc. and the other signatories thereto.

Exhibit 10.1 CONSENT AND TERMINATION AGREEMENT THIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), the undersigned securityholders of the Company (collectively

COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT

Exhibit 99.1 COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT THIS COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and between Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), on the one hand, and the undersigned securityholders (collectively, the “Securityholders

COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT

Exhibit 99.2 COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT THIS COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and between Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), on the one hand, and MSD Credit Opportunity Master Fund, L.P. a Cayman exempted limited

Company Securityholder Voting and Support Agreement, dated as of September 12, 2019, among Castle Creek Pharmaceutical Holdings, Inc. and the other signatories thereto.

EX-99.2 6 a2239675zex-992.htm EX-99.2 Exhibit 99.2 COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT THIS COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and between Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), on the one hand, and MSD Credit Opportunity Master

Consent and Termination Agreement, dated as of September 12, 2019, among Fibrocell Science, Inc. and the other signatories thereto.

Exhibit 10.1 CONSENT AND TERMINATION AGREEMENT THIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), the undersigned securityholders of the Company (collectively

Company Securityholder Voting and Support Agreement, dated as of September 12, 2019, between Castle Creek Pharmaceutical Holdings, Inc. and MSD Credit Opportunity Master Fund, L.P.

EX-99.1 5 a2239675zex-991.htm EX-99.1 Exhibit 99.1 COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT THIS COMPANY SECURITYHOLDER VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and between Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), on the one hand, and the undersigned securityholde

Consent and Termination Agreement, dated as of September 12, 2019, among Fibrocell Science, Inc., Castle Creek Pharmaceutical Holdings, Inc., Castle Creek Merger Corp. and MSD Credit Opportunity Master Fund, L.P.

Exhibit 10.2 CONSENT AND TERMINATION AGREEMENT THIS CONSENT AND TERMINATION AGREEMENT (hereinafter referred to as this “Agreement”) is made and entered into as of September 12, 2019 by and among Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Parent”), Fibrocell Science, Inc., a Delaware corporation (the “Company”), MSD Credit Opportunity Master Fund, L.P., a Cayman exempt lim

Agreement and Plan of Merger, dated as of September 12, 2019, among Fibrocell Science, Inc., Castle Creek Pharmaceutical Holdings, Inc., and Castle Creek Merger Corp.

EX-2.1 2 a2239675zex-21.htm EX-2.1 QuickLinks - Click here to rapidly navigate through this document Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among CASTLE CREEK PHARMACEUTICAL HOLDINGS, INC., CASTLE CREEK MERGER CORP. and FIBROCELL SCIENCE, INC. Dated as of September 12, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1. The Merger 2 1.2. Closing and Effective Time of the Merger 3 ARTI

FCSC / Fibrocell Science Inc. DEFA14A - - 8-K

QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

MEMORANDUM September 12, 2019

EX-99.2 3 a19-185873ex99d2.htm EX-99.2 Exhibit 99.2 MEMORANDUM September 12, 2019 To: All Fibrocell Science, Inc. Employees From: John Maslowski Re: Fibrocell to be Acquired by Castle Creek Pharmaceutical Holdings, Inc. This afternoon, we announced that Castle Creek Pharmaceutical Holdings, the parent company of Castle Creek Pharmaceuticals, LLC, has entered into a definitive agreement to acquire

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organi

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Cast

Exhibit 99.1 Castle Creek Pharmaceutical Holdings to Acquire Fibrocell - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, PA — September 12, 2019 — Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and

MEMORANDUM September 12, 2019

EX-99.2 3 a19-185873ex99d2.htm EX-99.2 Exhibit 99.2 MEMORANDUM September 12, 2019 To: All Fibrocell Science, Inc. Employees From: John Maslowski Re: Fibrocell to be Acquired by Castle Creek Pharmaceutical Holdings, Inc. This afternoon, we announced that Castle Creek Pharmaceutical Holdings, the parent company of Castle Creek Pharmaceuticals, LLC, has entered into a definitive agreement to acquire

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Cast

Exhibit 99.1 Castle Creek Pharmaceutical Holdings to Acquire Fibrocell - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, PA — September 12, 2019 — Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and

FCSC / Fibrocell Science Inc. DEFA14A - - 8-K

DEFA14A 1 a19-1858738k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdic

FCSC / Fibrocell Science Inc. S-8 - - S-8

As filed with the Securities and Exchange Commission on August 29, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizat

Amended and Restated Employment Agreement, dated August 20, 2019, by and between Fibrocell Science, Inc. and John M. Maslowski

Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”), is entered into as of August 20, 2019 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and John Maslowski (the “Executive”). Recitals WHEREAS, the Executive serves as the President and Chief Executive Officer of the Company

Employment Agreement, dated August 20, 2019, by and between Fibrocell Science, Inc. and Sean D. Buckley

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), is entered into as of August 20, 2019 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and Sean D. Buckley (the “Executive”). Recitals WHEREAS, the Executive serves as the Vice President of Business Administration and Corporate Secretary of the Company; and WHEREAS

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizat

Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, PA – August 14, 2019 – Fibrocell Science, Inc. (Nasdaq: FCSC), a

ex991081419finalfcscq220 Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.

Corporate Presentation August 14, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

ex992081419finalfibrocel Corporate Presentation August 14, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

August 14, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant as spe

Co-Development and License Agreement, dated April 12, 2019, by and between Castle Creek Pharmaceuticals, LLC and Fibrocell Science, Inc.

EX-10.5 2 ex105castlecreekfibrocel.htm EXHIBIT 10.5 Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. Omissions are designated as [**] FIBROCELL SCIENCE, INC. AND CASTLE CREEK PHARMACEUTICALS, LLC CO-DEVELOPMENT AND LICENSE AGREEMENT April 12, 2019 US-DOCS\106669270.9 TABLE OF CONTEN

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Corporate Presentation July 1, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that ar

ex991finalfibrocellcorpo Corporate Presentation July 1, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Form of Award Agreement - ISO Grant Employee

EX-10.2 3 ex102fibrocellisograntee.htm EXHIBIT 10.2 Ex. 10.2 FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION GRANT This STOCK OPTION GRANT, dated as of , (the “Date of Grant”), is delivered by Fibrocell Science, Inc. (the “Company”) to (the “Grantee”). RECITALS The Fibrocell Science, Inc. 2019 Equity Incentive Plan (the “Plan”) provides for the grant of options to purchas

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizatio

Form of Award Agreement - NQ Grant Director

Ex. 10.4 FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION GRANT (for Directors) This STOCK OPTION GRANT, dated as of (the “Date of Grant”), is delivered by Fibrocell Science, Inc. (the “Company”) to (the “Grantee”). RECITALS The Fibrocell Science, Inc. 2019 Equity Incentive Plan (the “Plan”) provides for the grant of options to purchase shares of common stock of the Com

Fibrocell Science, Inc. 2019 Equity Incentive Plan

Ex. 10.1 FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN Effective as of June 12, 2019 1. Purpose and Objectives The Fibrocell Science, Inc. 2019 Equity Incentive Plan (the “Plan”), is designed to align the interests of (i) designated employees of Fibrocell Science, Inc. (the “Company”) and its subsidiaries, (ii) non-employee members of the board of directors of the Company, and (iii) consultan

Form of Award Agreement - NQ Grant Employee

EX-10.3 4 ex103fibrocellnqgrantee.htm EXHIBIT 10.3 Ex. 10.3 FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION GRANT This STOCK OPTION GRANT, dated as of (the “Date of Grant”), is delivered by Fibrocell Science, Inc. (the “Company”) to (the “Grantee”). RECITALS The Fibrocell Science, Inc. 2019 Equity Incentive Plan (the “Plan”) provides for the grant of options to purchas

Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB EXTON, PA – May 29, 2019 – Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autolog

ex991052919finalfcx007rm Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB EXTON, PA – May 29, 2019 – Fibrocell Science, Inc.

Corporate Presentation May 29, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that ar

ex992052919finalfibrocel Corporate Presentation May 29, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Corporate Presentation May 15, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that ar

ex992finalfibrocellcorpo Corporate Presentation May 15, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA – May 15, 2019 – Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company

ex991finalfcsc1q19earnin Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

May 15, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant as sp

FCSC / Fibrocell Science Inc. DEFA14A DEFA14A

DEFA14A 1 formdefa14a42919.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rul

Definitive Proxy Statement on Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy - Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gros

ex991finalfcscccppa Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy - Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease Priority Review Voucher - - Phase 3 clinical trial (DEFI-RDEB) initiation expected in second quarter of 2019 - - Fibrocell to host conference call at 8:30 AM EDT Today - EXTON, Pa.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 - Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from P

ex991finalfcscfdameeting Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007 - Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well tolerated with continued positive trends in wound healing - - Company reports full year 2018 financial results - - Conference call & webcast scheduled at 8:30 a.

Corporate Presentation March 27, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

ex992finalfibrocellcorpo Corporate Presentation March 27, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

Annual Report on Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 OR ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Fibrocell Science, Inc. (Exact name of registrant as specified in its Charter.) Delaware 001-

List of Subsidiaries

Exhibit 21 List of Subsidiaries Fibrocell Technologies, Inc., a Delaware corporation (wholly owned by Fibrocell Science, Inc.) Isolagen International, S.A., a company organized under the laws of Switzerland (wholly owned by Fibrocell Technologies, Inc.)

FCSC / Fibrocell Science Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment

CUSIP No: 315721407 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Fibrocell Science, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 315721407 (CUSIP Numb

FCSC / Fibrocell Science Inc. / Frigate Ventures LP - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No.

FCSC / Fibrocell Science Inc.

CORRESP 1 filename1.htm Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 February 11, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Todd Schiffman Re: Fibrocell Science, Inc. Registration Statement on Form S-3 Filed January 18, 2019 File No. 333-229307 Request for Acceleration Ladies a

FCSC / Fibrocell Science Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13g1218a1intracofibrocell.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fibrocell Science, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 315721407 (CUSIP Number) December 31, 2018 (Date of Event Which Re

Common Stock Issuance Agreement, dated as of December 7, 2018, by and among Fibrocell Science, Inc. and EB Research Partnership, Inc. and Epidermolysis Bullosa Medical Research Foundation

exhibit101commonstockagr Exhibit 10.1 Execution Version \\PH - 036137/000006 - 396952 v6 COMMON STOCK ISSUANCE AGREEMENT THIS COMMON STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of December 7, 2018, by and among Fibrocell Science, Inc., a Delaware corporation (the “Company”), and EB Research Partnership, Inc., a New York not-for-profit corporation (“EBRP”), and Epidermolysis Bullosa Medi

FCSC / Fibrocell Science Inc. S-3

As filed with the Securities and Exchange Commission on January 18, 2019 Registration Statement No.

Corporate Presentation January 8, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

a010819jpmfinalfibrocell Corporate Presentation January 8, 2019 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2019 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizat

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation – Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullo

ex991finalebrpebmrf Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation – Funding to Help Further Clinical Development of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa – EXTON, PA – December 11, 2018 – Fibrocell Science, Inc.

FCSC / Fibrocell Science Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant a

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Corporate Presentation November 13, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements th

ex992111218finalpresenta Corporate Presentation November 13, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recess

ex991111218finalearnings Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.

Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007 - Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 - EXTON, PA – October 25, 2018 – Fibrocell Science,

ex991fcscfdameetingpress Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007 - Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 - EXTON, PA – October 25, 2018 – Fibrocell Science, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiza

Corporate Presentation October 3, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

ex99110012018fibrocellco Corporate Presentation October 3, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizat

Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, PA – September 25, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autolo

ex991finalreleasefdagran Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, PA – September 25, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organi

Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma EXTON, PA – September 5, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous

ex991finalfcscfasttrackf Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma EXTON, PA – September 5, 2018 – Fibrocell Science, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Corporate Presentation September 5, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements th

ex992finalfibrocellcorpo Corporate Presentation September 5, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA – August 9, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused o

ex991080818finalfcsc2q18 Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.

Corporate Presentation August 9, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

ex992080818finalfibrocel Corporate Presentation August 9, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

FCSC / Fibrocell Science Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant as spe

FCSC / Fibrocell Science Inc. CORRESP

Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 August 7, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik Re: Fibrocell Science, Inc. Registration Statement on Form S-1(File No. 333-226397) Filed July 27, 2018 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 46

the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form S-1 filed with the Commission on July 27, 2018, and any amendment or report filed for the purpose of updating that description.

As filed with the Securities and Exchange Commission on July 27, 2018 Registration Statement No.

FCSC / Fibrocell Science Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fibrocell Science, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 315721407 (CUSIP Number) July 2, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K, filed July 5, 2018)

fcscexhibit42july2018rdo Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN

Exhibit 99.2 Fibrocell Announces Closing of $4.0 Million Registered Direct Offering EXTON, PA — July 5, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and con

fcscexhibit992closingpre Exhibit 99.2 Fibrocell Announces Closing of $4.0 Million Registered Direct Offering EXTON, PA — July 5, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 1,474,080 shar

Form of Securities Purchase Agreement

fcscexhibit101july2018rd Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 2, 2018, between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to t

Form of Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed July 5, 2018)

fcscexhibit41july2018rdo Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN

Exhibit 99.1 Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market EXTON, PA – July 2, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for sk

EX-99.1 6 fcscexhibit991finalpress.htm EXHIBIT 99.1 Exhibit 99.1 Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market EXTON, PA – July 2, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

1,474,080 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209077 PROSPECTUS SUPPLEMENT (to Prospectus dated February 9, 2016) 1,474,080 Shares of Common Stock We are offering 1,474,080 shares of our common stock, $0.001 par value per share, at a purchase price of $2.69 per share, to certain institutional and accredited investors pursuant to this prospectus supplement and the accompan

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizatio

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizatio

FCSC / Fibrocell Science Inc. / CVI Investments, Inc. - SC 13G Passive Investment

CUSIP No: 315721407 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Fibrocell Science, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 315721407 (CUSIP Numbe

FCSC / Fibrocell Science Inc. / Frigate Ventures LP - SC 13G Passive Investment

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Fibrocell Science, Inc.

JOINT FILING AGREEMENT

EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $.001 par value, of Fibrocell Science, Inc., a Delaware corporation, and further agree that

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K, filed May 31, 2018)

exhibit42formofpawarrant NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market EXTON, PA – May 29, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connec

a052918fcscfinalpressrel Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market EXTON, PA – May 29, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into definitive agreements with several institutional investors for

Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed May 31, 2018)

exhibit101spa Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 29, 2018, between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an

Fibrocell Announces Closing of $6.0 Million Registered Direct Offering EXTON, PA — May 31, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissu

exhibit992053118finalfcs Fibrocell Announces Closing of $6.0 Million Registered Direct Offering EXTON, PA — May 31, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of its previously announced registered direct offering of 2,038,224 shares of its com

Form of Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed May 31, 2018)

exhibit41formofcommonwar Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUAN

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

2,038,224 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209077 PROSPECTUS SUPPLEMENT (to Prospectus dated February 9, 2016) 2,038,224 Shares of Common Stock We are offering 2,038,224 shares of our common stock, $0.001 par value per share, at a purchase price of $2.85 per share, to certain institutional and accredited investors pursuant to this prospectus supplement and the accompan

FCSC / Fibrocell Science Inc. 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Certificate of Amendment of the Restated Certificate of Incorporation of Fibrocell Science, Inc., as amended, dated May 24, 2018 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed on May 24, 2018)

exhibit31certificate STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF FIBROCELL SCIENCE, INC.

Fibrocell Announces One-for-Five Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on May 25, 2018 EXTON, PA – May 24, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformation

ex991finalreversesplit Fibrocell Announces One-for-Five Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on May 25, 2018 EXTON, PA – May 24, 2018 – Fibrocell Science, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa – FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wo

a052118finalfcscfcx007v9 Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa – FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring fibrils – – Company to Host Conference Call & Webcast Today at 8:30 am EDT– EXTON, PA – May 21, 2018 – Fibrocell Science, Inc.

FCX-007 Interim Data Update Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not hi

a051818fcsciidpresfinalv FCX-007 Interim Data Update Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA – May 10, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on t

a050818finalfcsc1q18earn Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.

Corporate Presentation May 10, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that ar

afinalfibrocellcorpora Corporate Presentation May 10, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

FCSC / Fibrocell Science Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant as sp

Fibrocell Announces Review of Strategic Alternatives EXTON, PA – April 18, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, toda

a041718finalfcscreleasev Fibrocell Announces Review of Strategic Alternatives EXTON, PA – April 18, 2018 – Fibrocell Science, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

FCSC / Fibrocell Science Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

FCSC / Fibrocell Science Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State

FCSC / Fibrocell Science Inc. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State

FCSC / Fibrocell Science Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 OR ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Fibrocell Science, Inc. (Exact name of registrant as specified in its Charter.) Delaware 001-

List of Subsidiaries

Exhibit 21 List of Subsidiaries Fibrocell Technologies, Inc., a Delaware corporation (wholly owned by Fibrocell Science, Inc.) Isolagen International, S.A., a company organized under the laws of Switzerland (wholly owned by Fibrocell Technologies, Inc.)

Corporate Presentation March 19, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

a031618finalfcsccorporat Corporate Presentation March 19, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

Fibrocell Reports 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA – March 19, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformatio

a031618finalfcscfy2017ea Fibrocell Reports 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.

Corporate Presentation March 6, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that a

a030518finalfcsccorporat Corporate Presentation March 6, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizati

Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma EXTON, PA — March 6, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on

fcsc030518finalfcscfcx01 Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma EXTON, PA — March 6, 2018 — Fibrocell Science, Inc.

Corporate Presentation February 12, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements th

a021218finalfcsccorporat Corporate Presentation February 12, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Financial Statements and Exhibits, Other Events

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation o

Corporate Presentation February 5, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements tha

a020518finalfcsccorporat Corporate Presentation February 5, 2018 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Financial Statements and Exhibits, Other Events

8-K 1 fcsc20518form8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdict

Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma EXTON, PA — February 5, 2018 — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on

a020218finalfcx013indrel Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma EXTON, PA ? February 5, 2018 ? Fibrocell Science, Inc.

Financial Statements and Exhibits, Other Events

8-K 1 fcsc13018form8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdicti

Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) EXTON, PA – January 30, 2018 – Fibrocell Science, Inc. (NASDAQ: FCSC), a

a012918finalreleasefcx00 Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) EXTON, PA – January 30, 2018 – Fibrocell Science, Inc.

FCSC / Fibrocell Science Inc. 8-K (Current Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or

Other Events

8-K 1 fcsc122917form8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdic

Corporate Presentation December 29, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements th

a12292017finalfcsccorpor Corporate Presentation December 29, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

FCSC / Fibrocell Science Inc. / KIRK RANDAL J - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Exhibit 1

EX-99.1 2 ex991.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Fibrocell Science, Inc., and further agree that this Joint Filing A

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiza

Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering

Exhibit 99.1 Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering EXTON, PA ? December 7, 2017 ? Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the pricing of an underwritten public offering of 13,636,364 shares of its common stock (Common Stock)

Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

Exhibit 99.2 Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering EXTON, PA ? December 11, 2017 ? Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of the previously announced underwritten public offering of 13,636,364 shares of its comm

Form of Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K, filed December 11, 2017)

Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: Issue Date: , 2017 Initial Exercise Date: , 2017 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

7,714,156 Shares of Common Stock Pre-Funded Warrants to Purchase 5,922,208 Shares of Common Stock Warrants to Purchase 13,636,364 Shares of Common Stock Fibrocell Science, Inc. UNDERWRITING AGREEMENT

Exhibit 1.1 Execution Version 7,714,156 Shares of Common Stock Pre-Funded Warrants to Purchase 5,922,208 Shares of Common Stock and Warrants to Purchase 13,636,364 Shares of Common Stock Fibrocell Science, Inc. UNDERWRITING AGREEMENT December 7, 2017 H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, New York 10022 Ladies and Gentlemen: Fibrocell Science, Inc. a Delaware corporation (

Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K, filed December 11, 2017)

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: Issue Date: , 2017 Initial Exercise Date: , 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof

Form of Underwriter’s Common Stock Purchase Warrant issued in December 2017 offering (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed December 11, 2017)

Exhibit 4.1 UNDERWRITER?S COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2017 Issue Date: [ ], 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Fibrocell Science, Inc. 7,714,156 Units (each Unit contains one Share of Common Stock and one Common Warrant to purchase one Share of Common Stock) 5,922,208 Pre-funded Units (each Pre-funded Unit contains one Pre-funded Warrant to Purchase one Share

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No.

FCSC / Fibrocell Science Inc. POS EX

QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on December 7, 2017 Registration Statement No.

Form of Pre-funded Common Stock Purchase Warrant

Exhibit 4.9 PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: Issue Date: , 2017 Initial Exercise Date: , 2017 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Form of Underwriting Agreement

Exhibit 1.1 [?] Shares of Common Stock Pre-Funded Warrants to Purchase [?] Shares of Common Stock and Warrants to Purchase [?] Shares of Common Stock Fibrocell Science, Inc. UNDERWRITING AGREEMENT [?], 2017 H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, New York 10022 Ladies and Gentlemen: Fibrocell Science, Inc. a Delaware corporation (the ?Company?), proposes to issue and sell t

Form of Common Stock Purchase Warrant

Exhibit 4.8 COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: Issue Date: , 2017 Initial Exercise Date: , 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof

Form of Underwriter's Common Stock Purchase Warrant

Exhibit 4.7 UNDERWRITER?S COMMON STOCK PURCHASE WARRANT FIBROCELL SCIENCE, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2017 Issue Date: [ ], 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

FCSC / Fibrocell Science Inc. S-1/A

QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on December 5, 2017 Registration Statement No.

FCSC / Fibrocell Science Inc. ESP

December 5, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, DC 20549 Re: Fibrocell Science, Inc. Registration Statement on Form S-1 (File No. 333-221375) Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (?Wainwright?), as underwriter for the referenced offering, hereby concurs in the request

FCSC / Fibrocell Science Inc. ESP

Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 December 5, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Fibrocell Science, Inc. Registration Statement on Form S-1(File No. 333-221375) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the Genera

FCSC / Fibrocell Science Inc. S-1/A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 4, 2017 Registration Statement No.

Corporate Presentation November 15, 2017 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-221375 Dated November 16, 2017

Corporate Presentation November 15, 2017 Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No.

FCSC / Fibrocell Science Inc. S-1/A

Table of Contents As filed with the Securities and Exchange Commission on November 16, 2017 Registration Statement No.

Corporate Presentation November 15, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements th

a111517finalfcsccorporat Corporate Presentation November 15, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

FCSC / Fibrocell Science Inc. 8-K (Current Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation o

Financial Statements and Exhibits, Results of Operations and Financial Condition

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation o

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

Exhibit Exhibit 99.1 Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - EXTON, PA - November 13, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results fo

Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

Exhibit Exhibit 99.1 Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - EXTON, PA - November 13, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results fo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorp

FCSC / Fibrocell Science Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant a

Power of attorney (included on the signature page of the registration statement filed on November 6, 2017)

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 6, 2017 Registration Statement No.

Other Events

8-K 1 fcsc100417form8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 04, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdict

Corporate Presentation October 4, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

ex991corppres100417 Corporate Presentation October 4, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Other Events

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation

Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa - FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends noted

Exhibit Exhibit 99.1 Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa - FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends noted in wound healing and pharmacology signals - - Data Safety Monitoring Board recommends continued enrollment and dosing - EXTON, P

Fibrocell Science 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or O

Corporate Presentation August 9, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

exhibit992corporateprese Corporate Presentation August 9, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -

Exhibit Exhibit 99.1 Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA - August 9, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for

FCSC / Fibrocell Science Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registrant as spe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organizatio

Fibrocell Science 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Or

Corporate Presentation June 21, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that a

fcsccorppresentation0621 Corporate Presentation June 21, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Corporate Presentation May 22, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that ar

fcsccorporatepres052217 Corporate Presentation May 22, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Development of an Autologous Gene-Modified Cell Therapy for the Treatment of Linear Scleroderma Tathagata Chaudhuri,1 Scott Moncrief,1 Anna Malyala,2 John Maslowski,2 Darby L. Thomas1 1Intrexon Corporation, Germantown MD; 2Fibrocell, Exton PA Present

asgct2017presentationfcx Development of an Autologous Gene-Modified Cell Therapy for the Treatment of Linear Scleroderma Tathagata Chaudhuri,1 Scott Moncrief,1 Anna Malyala,2 John Maslowski,2 Darby L.

Preclinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Marion Chakiath,1 Nazanin-Ehsani-Chimeh, 2 Ngon Nguyen, 2 Scott Moncrief, 1 Darby Thomas, 1 Ann

finalasgctfcx007oralpres Preclinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Marion Chakiath,1 Nazanin-Ehsani-Chimeh, 2 Ngon Nguyen, 2 Scott Moncrief, 1 Darby Thomas, 1 Anna Malyala,3 John Maslowski, 3 Peter Marinkovich2 1Intrexon Corporation, Germantown, MD; 2Stanford University School of Medicine, Stanford, PA; 3Fibrocell, Exton, PA Presented at the 20th Annual American Society of Gene & Cell Therapy Meeting, Washington, DC, May 11, 2017 This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organization

Fibrocell Science FORM 10-Q (Quarterly Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-31564 Fibrocell Science, Inc. (Exact name of registr

Fibrocell Science, Inc. 2009 Equity Incentive Plan, as amended and restated as of March 11, 2017 (incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed May 10, 2017)

Exhibit Exhibit 10.2 FIBROCELL SCIENCE, INC. 2009 EQUITY INCENTIVE PLAN (as amended and restated as of March 11, 2017) Table of Contents Page 1. Purpose and Objectives 2 2. Definitions 2 3 Administration 4 4. Grants 5 5. Shares Subject to the Plan 5 6. Eligibility for Participation 6 7. Options 6 8. Stock Units 9 9. Stock Awards 10 10. Stock Appreciation Rights and Other Stock-Based Awards 10 11.

Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -

Exhibit Exhibit 99.1 Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, PA - May 10, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial res

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Org

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Orga

Engagement Letter, dated May 8, 2017, by and between the Company and AC Lordi (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed May 9, 2017)

EX-10.1 2 exhibit101engagementletter.htm EXHIBIT 10.1 Exhibit 10.1 May 08, 2017 Mr. John M. Maslowski Chief Executive Officer Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, PA 19341 Dear John: On behalf of AC Lordi, we appreciate the opportunity to provide you with professional services. This Engagement Letter governs the relationship between the parties. Each engagement we perform for you

Fibrocell Science DEF 14A

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pr

Fibrocell Announces One-for-Three Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on March 13, 2017

Exhibit Exhibit 99.1 Fibrocell Announces One-for-Three Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on March 13, 2017 EXTON, PA - March 10, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it will effect a one-for-th

Certificate of Amendment of the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed March 10, 2017)

Exhibit Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF FIBROCELL SCIENCE, INC. Fibrocell Science, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?) for the purpose of amending its Restated Certificate of Incorporation, as amended, in accordance with the General Corporation Law of the State

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or O

FCSC / Fibrocell Science Inc. / KIRK RANDAL J - RANDAL J KIRK SC 13DA NO 6 3-8-2017 (FIBROCELL SCIENCE, INC) Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.

Exhibit 4

Exhibit 4 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Fibrocell Science, Inc.

Fibrocell Science FORM 10-K (Annual Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2016 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Fibrocell Science, Inc. (Exact name of registrant as specified in its Charter.) Dela

Fibrocell Reports 2016 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

EX-99.1 2 exhibit991pressrelease0309.htm EXHIBIT 99.1 Exhibit 99.1 Fibrocell Reports 2016 Financial Results and Recent Operational Highlights - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - EXTON, PA - March 9, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue disea

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Or

Separation Agreement and Release, dated November 4, 2016, and Supplemental Release, dated January 4, 2017, by and between the Company and Keith A. Goldan (incorporated by reference to Exhibit 10.24 to our Annual Report on Form 10-K, filed March 9, 2017)

Exhibit 10.24 SEPARATION AGREEMENT AND RELEASE THIS SEPARATION AGREEMENT AND RELEASE is made as of the last date signed below (the “Separation Agreement and Release”), between Keith A. Goldan (“Employee”) and Fibrocell Science, Inc. (the “Company”). WHEREAS, the Employee commenced employment with the Company on March 18, 2015 and now desires to terminate his employment; WHEREAS, in order to facili

Subsidiaries of Fibrocell Science, Inc. (incorporated by reference to Exhibit 21.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed March 09, 2017 (File No. 001-31564)

Exhibit 21 List of Subsidiaries Fibrocell Technologies, Inc., a Delaware corporation (wholly owned by Fibrocell Science, Inc.) Isolagen International, S.A., a company organized under the laws of Switzerland (wholly owned by Fibrocell Technologies, Inc.)

Form of Securities Purchase Agreement by and between the Company and other signatories thereto dated March 7, 2017 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed March 8, 2017)

Exhibit Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of March 7, 2017, by and among Fibrocell Science, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “ Purchaser ” and collectively, the “ Purchasers ”). WHEREAS, subject to the

RISK FACTORS

Exhibit Exhibit 99.1 RISK FACTORS Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common stock could decline and you may lose all o

Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million

Exhibit Exhibit 99.2 Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million EXTON, PA - March 7, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into a securities purchase agreement with certain of its existing investors

Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed March 8, 2017)

Exhibit Exhibit 3.1 FIBROCELL SCIENCE, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John M. Maslowski, does hereby certify that: 1. He is the Chief Executive Officer of Fibrocell Science, Inc., a Delaware corporation (the ?Corporation?). 2. The Corporat

Fibrocell Science, Inc. Computation of Ratio of Earnings to Fixed Charges and Preference Security Dividends For the Year Ended December 31, 2016 2015 2014 2013 2012 Earnings: Net loss before income taxes $ (15,292 ) $ (34,453 ) $ (25,650 ) $ (31,554

Exhibit Exhibit 12.1 Fibrocell Science, Inc. Computation of Ratio of Earnings to Fixed Charges and Preference Security Dividends For the Year Ended December 31, 2016 2015 2014 2013 2012 Earnings: Net loss before income taxes $ (15,292 ) $ (34,453 ) $ (25,650 ) $ (31,554 ) $ (15,643 ) Add: fixed charges 759 537 519 514 1,629 Less: minority interest in loss of subsidiaries with fixed charges ? ? ? ?

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Or

Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K, filed March 8, 2017)

Exhibit Exhibit 4.1 THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. This Warrant is issued pursuant to that certain Securities Purchase Agreement dated March 7, 2017 by and among the Company and the other parties signatory thereto (the ? Purchase Agreement ?) and is one of a series of similar warrants issued pur

8,000 Units, with each unit consisting of one share of Series A Convertible Preferred Stock and a Warrant to purchase 1,289 shares of Common Stock

Document Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-209077 PROSPECTUS SUPPLEMENT (to Prospectus dated February 9, 2016) 8,000 Units, with each unit consisting of one share of Series A Convertible Preferred Stock and a Warrant to purchase 1,289 shares of Common Stock We are offering shares of our Series A Convertible Preferred Stock, par value $0.001 per share (? Series

SUBJECT TO COMPLETION, DATED March 7, 2017

424B5 1 fcsc030717form424b5.htm FORM 424B5 Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not s

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Or

Separation Agreement and General Release by and between the Company and Kimberly M. Smith dated March 3, 2017 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed March 3, 2017)

Exhibit Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE NOTICE: YOU SHOULD THOROUGHLY REVIEW AND UNDERSTAND THE TERMS, CONDITIONS, AND EFFECT OF THIS SEPARATION AGREEMENT AND GENERAL RELEASE. YOU ARE ADVISED TO CONSULT WITH AN ATTORNEY BEFORE SIGNING IT. The parties to this Separation Agreement and General Release (hereinafter ?Agreement?) are Fibrocell Science, Inc. (the ?Company?) and Kimb

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Or

Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Exhibit Exhibit 99.1 Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, PA ? February 23, 2017 ? Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the f

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

FCSC / Fibrocell Science Inc. / PRUDENTIAL FINANCIAL INC Passive Investment

13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.

Fibrocell Science DEF 14A

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pr

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or

Separation Agreement and General Release by and between the Company and Michael F. Marino dated January 25, 2017 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed January 26, 2017)

Exhibit Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE NOTICE: YOU SHOULD THOROUGHLY REVIEW AND UNDERSTAND THE TERMS, CONDITIONS, AND EFFECT OF THIS SEPARATION AGREEMENT AND GENERAL RELEASE. YOU ARE ADVISED TO CONSULT WITH AN ATTORNEY BEFORE SIGNING IT. The parties to this Separation Agreement and General Release (hereinafter ?Agreement?) are Fibrocell Science, Inc. (the ?Company?) and Mich

Fibrocell Science PRE 14A

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Pr

Corporate Presentation January 9, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that

fcsccorporatepres010917 Corporate Presentation January 9, 2017 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.

Financial Statements and Exhibits, Other Events

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or

Fibrocell Science FORM 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2017 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or

Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Exhibit Exhibit 99.1 Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa EXTON, PA - January 5, 2017 - Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U. S. Food and Drug Administration (FDA) h

Fibrocell Announces Leadership Changes John Maslowski Succeeds David Pernock as Chief Executive Officer; Douglas Swirsky Appointed Chairman of the Board of Directors

Exhibit Exhibit 99.1 Fibrocell Announces Leadership Changes John Maslowski Succeeds David Pernock as Chief Executive Officer; Douglas Swirsky Appointed Chairman of the Board of Directors EXTON, PA - December 19, 2016 - Fibrocell Science, Inc. (NASDAQ: FCSC) today announced that John Maslowski has been appointed Chief Executive Officer (CEO) and Douglas Swirsky has been appointed Chairman of the Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2016 FIBROCELL SCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 001-31564 87-0458888 (State or Other Jurisdiction of Incorporation or Organiz

Separation Agreement and General Release by and between the Company and David Pernock dated December 18, 2016 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed December 19, 2016)

Exhibit Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE NOTICE: YOU SHOULD THOROUGHLY REVIEW AND UNDERSTAND THE TERMS, CONDITIONS, AND EFFECT OF THIS SEPARATION AGREEMENT AND GENERAL RELEASE. YOU ARE ADVISED TO CONSULT WITH AN ATTORNEY BEFORE SIGNING IT. The parties to this Separation Agreement and General Release (hereinafter ?Agreement?) are Fibrocell Science, Inc. (the ?Company?) and Davi

Offer Letter by and between the Company and John M. Maslowski dated December 18, 2016 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K, filed December 19, 2016)

Exhibit Exhibit 10.2 December 18, 2016 Dear Mr. Maslowski, This letter will confirm your appointment to serve as the Chief Executive Officer (?CEO?) of Fibrocell Science, Inc. (the ?Company?) and a member of the Board of Directors of the Company (the ?Board?), in each case effective as of December 16, 2016 (the ?Effective Date?). In your role as CEO, you will have all of the duties, responsibiliti